Global Proteomics Services Market to Reach $16.46 Billion by 2030

Advances in Multiplexing, Automation, and Multi-Omics Integration Reshaping the Proteomics Services Landscape

Published on Feb. 27, 2026

Got story updates? Submit your updates here. ›

The global proteomics services market is projected to reach $16.46 billion by 2030, growing at a CAGR of 13.4% from 2025. This robust growth is driven by accelerating advances in multiplexing technology, laboratory automation, and bioinformatics, which are transforming how organizations decode protein interactions, validate biomarkers, and generate insights across drug discovery, diagnostics, and translational research.

Why it matters

The expanding proteomics services sector represents a significant opportunity and critical operational consideration for executive decision-makers evaluating R&D investment strategies, competitive positioning, and outsourcing frameworks. Biopharmaceutical R&D outsourcing, rising adoption of companion diagnostics and biomarker panels, and the expansion of proteomics applications into precision medicine are intensifying demand for high-throughput, reproducible, and integrated proteomic workflows.

The details

The proteomics services ecosystem encompasses contract research organizations, core research facilities, biopharmaceutical companies, and clinical laboratories that deliver integrated analytical workflows spanning sample preparation, high-throughput mass spectrometry, targeted and quantitative proteomics, and advanced bioinformatics. Biopharmaceutical companies currently command the largest end-user share, reflecting their extensive reliance on proteomics for drug discovery, biomarker validation, and biologics development. Asia Pacific is positioned as the fastest-growing regional market, driven by expanding biopharma R&D capacity, strong biologics and precision therapy pipelines, and accelerating investments in advanced proteomics platforms.

  • The proteomics services market is projected to reach $16.46 billion by 2030.
  • The market is expected to grow at a CAGR of 13.4% from 2025 to 2030.

The players

Thermo Fisher Scientific

A leading provider of comprehensive solutions spanning mass spectrometry-based proteomics analysis, high-resolution protein quantification, label-free and isotope-based quantification, and protein-protein interaction mapping.

Danaher Corporation

Through subsidiaries Beckman Coulter and Cytiva, delivers high-throughput protein characterization, automated protein handling, and advanced chromatography platforms for quantitative proteomics and biomarker panel development.

Agilent Technologies

Combines high-performance mass spectrometry platforms with automated sample preparation and advanced bioinformatics solutions, offering quantitative proteomics, post-translational modification analysis, and customized proteome profiling.

Revvity

Extends its service portfolio with advanced proteomics bioinformatics and management software, offering automated analysis pipelines, protein interactome visualization, and post-translational modification analysis.

Illumina

Brings sequencing-enabled protein analysis and bead-based proteomic capabilities to the market, empowering researchers to develop functional protein biomarkers and interrogate the proteome at unprecedented scale.

Got photos? Submit your photos here. ›

The takeaway

The convergence of proteomics with other 'omics' technologies, such as genomics and metabolomics, is creating a new frontier in integrated multi-omics service delivery. Service providers that can offer comprehensive, cross-platform biological insights across drug development stages are poised to capture disproportionate market share and deliver higher-value solutions to their clients.